ArticleBMC genomics2026
Transcriptomic signatures of high‑intensity pyrethroid resistance in Anopheles gambiae from a Cameroonian agricultural hotspot.
Article in BMC genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPyrethroid resistance continues to undermine malaria vector control across Africa, particularly in agricultural hotspots where insecticide pressure is high. However, the molecular mechanisms enabling Anopheles gambiae to survive extreme pyrethroid doses remain poorly understood. This study investigates transcriptomic responses, allele‑frequency shifts, and selection signatures associated with high‑ permethrin resistance intensity in An. gambiae from Mangoum, Cameroon.
resultsRNA‑seq analyses revealed strong overexpression of detoxification genes in both unexposed and permethrin‑exposed field mosquitoes. The UDP‑glycosyltransferase UGT308G1 showed the highest expression levels (FC = 105.1 in C–S; 50.8 in R–S). Within the P450 family, members of the CYP6Z cluster were markedly overexpressed, notably CYP6Z3 (FC = 68.8 in C–S; 41.4 in R–S), CYP6Z2 (FC = 29.0; 17.2), and CYP6Z1 (FC = 12.3; 6.0). Additional detoxification genes such as CYP9K1 (FC = 11.3; 4.7), CYP6M2 (FC = 8.5; 3.8), and the cuticle‑associated CYP4G17 (FC = 2.9; 2.5) were strongly upregulated. Increasing permethrin doses (1 × , 5 × , 10 ×) induced further upregulation of oxidative‑stress, mitochondrial, and translational pathways. Gene‑level population‑genetic metrics revealed strong selective sweeps at VGSC and across the rp1 region. High‑frequency nonsynonymous variants in CYP6AA1 (Ser395Thr), CYP6AA2 (Asn327Asp), CYP6P1 (Ile168Val and Leu374Met), and the validated marker Glu205Asp-CYP6P3 were nearly fixed in field populations and absent in lab susceptible strain, consistent with long‑term selection and hitchhiking. Additional metabolic variants in CYP12F2, UGT49A3, UGT308A2, and ABCA2 occurred at moderate to high frequencies and distinguished resistant from susceptible genetic backgrounds. RNAi‑mediated silencing of CYP6Z1, CYP6Z2, CYP6Z3, and CYP6Z4 significantly increased mortality under permethrin and alpha‑cypermethrin 1X, 5X and 10X exposure, confirming the functional involvement of the CYP6Z family in resistance escalation.
conclusionsHigh pyrethroid resistance intensity in An. gambiae arises from strong target‑site selection coupled with extensive metabolic adaptation. The convergence of transcriptomic signals, allele‑frequency patterns, and RNAi assays highlights the CYP6Z genes cluster, together with key P450, UGT, and ABC variants, as central components of a polygenic resistance architecture. These findings underscore the need to integrate metabolic markers into resistance surveillance to detect and manage escalating pyrethroid resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.